PSMA-Targeted Therapy May Decrease PSA Levels in Metastatic Prostate Cancer Subset
May 1st 2023Patients with metastatic castration-resistant prostate cancer treated with radioligand therapy, a form of targeted therapy, had improvements in PSA levels and survival with favorable side effect profiles.
Read More